排序方式: 共有263条查询结果,搜索用时 0 毫秒
261.
Azadeh Hosseini-Tabatabaei Hadi Esmaily Reza Rahimian Reza Khorasani Maryam Baeeri Ahmadreza Barazesh-Morgani Fatemeh Sari-Aslani Mohammad Abdollahi 《Central European Journal of Biology》2009,4(1):74-85
Inflammatory bowel disease (IBD) is a chronic inflammatory condition with an unknown etiology. Nicorandil, a potassium channel
opener, has been used for many years for the treatment of angina. Recently, it has been shown that nicorandil possesses some
novel traits such as anti-apoptotic, gastroprotective, free radical scavenging, and anti-inflammatory properties. Therefore,
we set out to examine the possible beneficial effect of nicorandil in a rat model of IBD. Colitis was induced by rectal administration
of 2,4,6-trintrobenzene sulphonic acid (TNBS) into rats. Groups of animals used in this study were sham, control, and exposure
to dexamethasone, nicorandil, glibenclamid (a pure adenosine triphosphate sensitive potassium channel (KATP) blocker), or
nicorandil plus glibenclamid. Drugs were administered by gavage and animals were sacrificed after 7 days. Biochemical markers,
including TNF-α and IL-1β, ferric reducing/antioxidant power (FRAP), myeloperoxidase (MPO) activity and thiobarbitoric acid-reactive
substance (TBARS), were measured in the homogenate of colonic tissue. Results indicate that nicorandil significantly reduces
macroscopic and histological damage induced by TNBS. Nicorandil diminishes MPO activity and levels of TBARS, TNF-∢, and IL-1β
in damaged colonic tissue with a concomitant increase in FRAP value (P<0.01). These effects were not reversed by coadministration
of glibenclamide. In conclusion, nicorandil is able to ameliorate experimental IBD with a dose in which it does not show any
anti-hypertensive effect, and the mechanism of which is partially or totally independent from KATP channels. It is hypothesized
that nitric oxide donation and free-radical scavenging properties of nicorandil upregulate endothelial nitric oxide synthase
may be responsible for this phenomenon. These findings suggest that nicorandil can be useful in treatment of IBD, although
further investigations are needed to elucidate the mechanisms involved. 相似文献
262.
Bahman Yousefi Saeid Valizadeh Hadi Ghaffari Azadeh Vahedi Mohsen Karbalaei Majid Eslami 《Journal of cellular physiology》2020,235(12):9133-9142
In late December 2019 in Wuhan, China, several patients with viral pneumonia were identified as 2019 novel coronavirus (2019-nCoV). So far, there are no specific treatments for patients with coronavirus disease-19 (COVID-19), and the treatments available today are based on previous experience with similar viruses such as severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Influenza virus. In this article, we have tried to reach a therapeutic window of drugs available to patients with COVID-19. Cathepsin L is required for entry of the 2019-nCoV virus into the cell as target teicoplanin inhibits virus replication. Angiotensin-converting-enzyme 2 (ACE2) in soluble form as a recombinant protein can prevent the spread of coronavirus by restricting binding and entry. In patients with COVID-19, hydroxychloroquine decreases the inflammatory response and cytokine storm, but overdose causes toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and zanamivir are invalid for 2019-nCoV and are not recommended for treatment but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the progression of MERS-CoV disease and can be useful for patients of COVID-19 and, in combination with Arbidol, has a direct antiviral effect on early replication of SARS-CoV. Ribavirin reduces hemoglobin concentrations in respiratory patients, and remdesivir improves respiratory symptoms. Use of ribavirin in combination with LPV/r in patients with SARS-CoV reduces acute respiratory distress syndrome and mortality, which has a significant protective effect with the addition of corticosteroids. Favipiravir increases clinical recovery and reduces respiratory problems and has a stronger antiviral effect than LPV/r. currently, appropriate treatment for patients with COVID-19 is an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids. 相似文献
263.
Power density and duty factor values were measured around smart utility meters operating at 868 MHz under laboratory-controlled conditions. The maximum 6-min averaged exposure recorded was 0.1 mWm−2, which is less than 0.0024% of the corresponding 1998 ICNIRP general public reference level. Duty factors measured were less than 2.8%. This study found that the exposure contribution from Zigbee smart meter devices operating at 868 MHz is generally lower than, if not similar to, those operating at 2.4 GHz. © 2023 Crown copyright. Bioelectromagnetics published by Wiley Periodicals LLC on behalf of Bioelectromagnetics Society. 相似文献